December 15 - December 17, 2022 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC), Pharmacology and Molecular Mechanisms (PAMM) group
Oct 7, 2026 Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Sep 29, 2026 Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
